COSCIENS Biopharma (TSE:CSCI) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
COSCIENS Biopharma Inc., a biopharmaceutical company known for its diverse portfolio including the FDA-approved oral test for adult growth hormone deficiency, has announced the immediate resignation of Carolyn Egbert from its Board of Directors. The company expressed gratitude for Egbert’s contributions, particularly during her eight years as Chair, and revealed plans to restructure the Board to consist of six members. This move is aimed to align with industry standards for a company at COSCIENS’ stage of development.
For further insights into TSE:CSCI stock, check out TipRanks’ Stock Analysis page.